Post-Intensification Treatment Strategies for EGFR-Mutant NSCLC

The most challenging scenario involves patients who received frontline chemotherapy-osimertinib combinations and subsequently progress. Dr. Camidge reviews subgroup data from FLAURA-2 showing that approximately 70% of progressive patients received subsequent chemotherapy, with differences based on prior platinum exposure.

Patients receiving initial osimertinib monotherapy typically received platinum-pemetrexed at progression, whereas those receiving upfront chemotherapy-osimertinib received only 40% platinum rechallenge rates. The analysis suggests platinum rechallenge patients achieved favorable overall survival, though selection bias affects interpretation.

Dr. Camidge believes platinum rechallenge is reasonable with adequate treatment-free intervals, noting that prolonged cancer control with targeted therapy may reverse selection pressures maintaining platinum resistance. One-year platinum-free intervals merit rechallenge consideration.

Dr. Rotow emphasizes exhausting each treatment line's benefit before progression, as returning to previously used therapies becomes increasingly difficult. For patients completing FLAURA-2 maintenance, datopotamab deruxtecan represents the logical next step. However, patients with extended platinum-free intervals present complex decision-making scenarios lacking definitive guidance.

The panel agrees that 6-month platinum-free intervals represent reasonable rechallenge thresholds, though acknowledging limited data supporting specific cutoffs. For rechallenge decisions, Dr. Rotow prefers MARIPOSA-2 approaches that modify the regimen rather than simple platinum re-administration.

The discussion highlights significant knowledge gaps in post-combination therapy sequencing, representing an area requiring additional research to optimize patient outcomes in this increasingly common clinical scenario.